Bausch And Lomb's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bausch And Lomb (BLCO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bausch And Lomb vs Its Competitors
- TTM: Trailing 12-month revenue of 5,418M vs 102,854M combined for its competitors (5.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.5% annualized vs trailing 12 months), vs accelerating (+2.3%) for its tracked peer group.
- Growth: Bausch And Lomb generated 7.3% revenue growth year over year in Q3 2026, vs 5.9% for its competitors combined.
- Profitability: Its 2.3% net margin compares with 1.6% for the peer group.
- Scale: Bausch And Lomb ranks #29 of 246 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.5% of industry market cap.
- Peer revenue share: Bausch And Lomb accounted for 5.0% of combined revenue among its tracked peer group, up from 4.9% a year earlier.
- Peer differentiation: Revenue per employee of $0.42M compares with $0.62M for the peer group (0.7x).
- Structure: Bausch And Lomb operates in the following segments: Vision Care, Pharmaceuticals, Surgical.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BLCO Sales vs. its Competitors, Q3 2026
Bausch And Lomb reported revenue growth of 7.34 % year on year in Q3 2026, above its competitors' combined revenue growth of 5.92 %.
With a net margin of 2.33 %, Bausch And Lomb achieved higher profitability than its competitors (1.55 %).
Bausch And Lomb generated 4.97 % of the combined sales of its peer group, up from 4.91 % a year earlier.
API endpoints for this dataset
Bausch And Lomb vs. its Competitors, Q3 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Bausch And Lomb reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Bausch And Lomb and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Bausch and Lomb Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Bausch And Lomb's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 7.3% for Bausch And Lomb. Bausch And Lomb's share of combined industry revenue moved from 1.26% to 1.18%, a loss of 0.08 percentage points.
Bausch And Lomb's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bausch and Lomb Corp | No | Yes | Yes | No |
| Competitors combined (13) | ||||
| High-Confidence Competitors (18) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BLCO Stock Performance relative to its Competitors
BLCO Stock Performance relative to High-Confidence Competitors
BLCO Stock Performance relative to Similar-Size Competitors
BLCO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Johnson and Johnson | 282.9% | Outperformed |
| 2 | West Pharmaceutical Services Inc | 282.9% | Outperformed |
| 3 | Warby Parker Inc | 282.9% | Outperformed |
| 4 | Novartis Ag | 282.9% | Outperformed |
| 5 | Masimo Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bausch And Lomb's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bausch And Lomb's Comment on Competition and Industry Peers
Publicly Traded Peers of Bausch and Lomb Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Bausch and Lomb Corp |
7,226.38 | 5,418.00 |
 Johnson and Johnson |
676,352.29 | 99,335.00 |
 Novartis Ag |
317,785.25 | 56,674.00 |
 Alcon inc |
37,185.23 | 10,401.00 |
 West Pharmaceutical Services Inc |
28,306.55 | 3,397.10 |
 The Cooper Companies Inc |
12,060.42 | 4,236.60 |
| SUBTOTAL | 1,094,591.36 | 184,428.65 |
Sign in to see all competitors of Bausch and Lomb Corp.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bausch and Lomb Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bausch And Lomb's Competitors Named by the Company
Competitive relationships identified from Bausch And Lomb reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Alcon inc | Company report | 85% |
| Cutera Inc | Company report | 85% |
| Staar Surgical Co | Company report | 85% |
| Spyglass Pharma Inc | Company report | 85% |
| Lenz Therapeutics Inc | Company report | 85% |
| DURECT Corporation | Company report | 85% |
| Reshape Lifesciences Inc | Company report | 85% |
| Escalon Medical Corp | Company report | 85% |
| Evolus Inc | Company report | 85% |
| Essa Pharma inc | Company report | 85% |
| Oculis Holding Ag | Company report | 85% |
| Waldencast Plc | Company report | 85% |
| Skye Bioscience Inc | Company report | 85% |
| Prestige Consumer Healthcare Inc | Company report | 85% |
| Halozyme Therapeutics Inc | Company report | 85% |
| Sol gel Technologies Ltd | Company report | 85% |
| Vyne Therapeutics Inc | Company report | 85% |
| Jaguar Health Inc | Company report | 85% |
| The Cooper Companies Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Novartis Ag | Company report | 85% |
| Horizon Therapeutics Public Limited Company | Company report | 85% |
| Rxsight Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Mallinckrodt Plc | Company report | 85% |
| Outlook Therapeutics Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Collegium Pharmaceutical Inc | Company report | 85% |
| Iridex Corp | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Sanofi | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Eton Pharmaceuticals Inc | Company report | 85% |
| Lifecore Biomedical Inc | Company report | 85% |
| Revance Therapeutics Inc | Company report | 85% |
| Assertio Holdings inc | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Indivior Pharmaceuticals Inc | Company report | 85% |
| National Vision Holdings Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Bausch And Lomb's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Bausch And Lomb's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bausch and Lomb Corp | Vision Care 56.29 % |
| Johnson and Johnson | Oncology 29.93 % |
| West Pharmaceutical Services Inc | Proprietary Products 83.34 % |
| The Cooper Companies Inc | CooperVision 67.93 % |
| Masimo Corp | Health Care 99.95 % |
| Warby Parker Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Bausch and Lomb Corp.
Bausch And Lomb's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bausch and Lomb Corp | 7,226 | 416,769 | -8,154 |
| Johnson and Johnson | 676,352 | 705,504 | 114,311 |
| Novartis Ag | 317,785 | 752,973 | 185,566 |
| Alcon inc | 37,185 | 416,040 | 39,200 |
| West Pharmaceutical Services Inc | 28,307 | 314,546 | 59,157 |
| The Cooper Companies Inc | 12,060 | 282,440 | 38,020 |
| PEERS TOTAL | 1,087,365 | 622,124 | 112,122 |
Sign in to see all peers for Bausch and Lomb Corp.
Bausch And Lomb's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Johnson and Johnson | United States 58.90 % |
| The Cooper Companies Inc | United States 50.22 % |
| Staar Surgical Co | Geographic Distribution Foreign 47.12 % |
| Femasys Inc | US 97.83 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Bausch And Lomb's Position in Industry Market Structure
Market-capitalization share and concentration across all 218 companies in Bausch And Lomb's industry classification, broader than the peer set above. Market cap in millions of $.Bausch And Lomb ranks #29 of 218 companies by market capitalization in its industry, holding 0.49 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 616, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Intuitive Surgical Inc | 161,785 | 13.52 % |
| 2 | Medtronic Plc | 130,823 | 10.94 % |
| 3 | Stryker Corp | 125,786 | 10.51 % |
| 4 | 3m Company | 96,722 | 8.09 % |
| 5 | Boston Scientific Corporation | 1,234 | 5.2% |
| 6 | Edwards Lifesciences Corporation | 1,234 | 5.2% |
| 7 | Becton Dickinson And Company | 1,234 | 5.2% |
| 8 | Alcon inc | 1,234 | 5.2% |
| 9 | Resmed Inc | 1,234 | 5.2% |
| 10 | Medline Inc | 1,234 | 5.2% |
| 29 | Bausch and Lomb Corp | 5,919 | 0.49 % |
Market cap and industry share for the rest of Bausch And Lomb's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-26.
Bausch And Lomb's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 24 | Henry Schein Inc | 9,843 | 18.55 % |
| 25 | Globus Medical Inc | 9,761 | 21.70 % |
| 26 | Modular Medical Inc | 7,251 | -91.48 % |
| 27 | Teleflex Incorporated | 6,587 | 17.63 % |
| 28 | Msa Safety Inc | 1,234 | 12.3% |
| 30 | Haemonetics Corporation | 1,234 | 12.3% |
| 31 | Lifestance Health Group Inc | 1,234 | 12.3% |
| 32 | Merit Medical Systems Inc | 1,234 | 12.3% |
| 33 | Livanova Plc | 1,234 | 12.3% |
| 34 | Marizyme Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bausch And Lomb's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-06. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bausch And Lomb's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 37.62 % | 46.21 % (avg) | -8.6 pp |
| Operating Margin | 7.07 % | industry median | +1.9 pp |
| EBITDA Margin | 11.20 % | -6.74 % (avg) | +17.9 pp |
| Capital Intensity (Capex / Revenue) | 5.57 % | 7.15 % (avg) | -1.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Bausch And Lomb's Valuation vs Competitive Position
Valuation multiples vs the Medical Equipment & Supplies industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Equipment & Supplies industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 37.6x | - |
| EV / EBITDA | 13.6x | 17.9x | -4.3x |
| P/B | 0.9x | 4.6x | -3.7x |
| Return on Equity | -1.64 % | industry aggregate | -16.97 % |
| Return on Invested Capital | 2.06 % | -6.81 % (avg) | 8.87 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bausch And Lomb's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | 10.03 % | 15.56 % | 6.47 % |
| Operating Margin | 5.49 % | 3.14 % | 3.38 % | 2.22 % |
| Return on Invested Capital | 1.23 % | 0.72 % | 0.88 % | 0.61 % |
| P/E | 903.3x | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bausch And Lomb's Strategic Group Map
Bausch And Lomb is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Bausch And Lomb's trailing-12-month revenue growth of 8.9% and operating margin of 7.1% compares with an average of 8.9% growth and 7.4% margin across its 8 closest peers by combined growth, margin and ROIC -- Bausch And Lomb sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Bausch And Lomb's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Bausch And Lomb falls in the Dog quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 8.8% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bausch And Lomb's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 616 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 5.57 % vs industry average 7.15 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Bausch And Lomb's dedicated Suppliers and Customers pages, not here.
Bausch And Lomb's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Bausch And Lomb falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bausch And Lomb's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Return on equity 17.0 points below the industry aggregate.
- Low relative market share vs the industry leader (0.04x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Bausch And Lomb's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bausch and Lomb Corp | 0.20 | 1.55 | 0.39 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Alcon inc | 0.50 | 2.12 | 0.19 |
| West Pharmaceutical Services Inc | 0.85 | 2.84 | 0.07 |
| The Cooper Companies Inc | 0.09 | 1.49 | 0.30 |
Sign in to see all peers for Bausch and Lomb Corp.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bausch And Lomb's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bausch and Lomb Corp | Q3 2026 | +7.3 % | - |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Alcon inc | Q4 2025 | +4.9 % | -3.7 % |
| West Pharmaceutical Services Inc | Q3 2026 | +8.7 % | +52.9 % |
| The Cooper Companies Inc | Q2 2026 | +0.6 % | +340.3 % |
| PEERS TOTAL | +7.9 % | -12.3 % |
Sign in to see all peers for Bausch and Lomb Corp.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bausch And Lomb's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bausch and Lomb Corp | Q3 2026 | +91.0 % | -25.7 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Alcon inc | Q4 2025 | +6.1 % | +14.8 % |
| West Pharmaceutical Services Inc | Q3 2026 | +3.4 % | -38.2 % |
| The Cooper Companies Inc | Q2 2026 | -3.7 % | -29.1 % |
Sign in to see all peers for Bausch and Lomb Corp.
Bausch And Lomb's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bausch and Lomb Corp | - | - | - |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Alcon inc | 3.11% | 3.47% | 4.45% |
| West Pharmaceutical Services Inc | 15.47% | 17.65% | 21.08% |
| The Cooper Companies Inc | 4.57% | 5.09% | 6.90% |
Sign in to see all peers for Bausch and Lomb Corp.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bausch And Lomb's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bausch and Lomb Corp | - | 1.33 |
| Johnson and Johnson | 41.79 | 6.81 |
| Novartis Ag | 22.73 | 5.61 |
| Alcon inc | 37.85 | 3.58 |
| West Pharmaceutical Services Inc | 44.87 | 8.33 |
| The Cooper Companies Inc | 21.36 | 2.85 |
| PEERS AVERAGE | 34.04 | 5.94 |
Sign in to see all peers for Bausch and Lomb Corp.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.